Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: protocol for the COL-ECMO2022 trial - a prospective, non-randomised, open-label phase IV pharmacokinetic clinical trial

P. Suk, J. Rychlíčková, L. Součková, V. Kubíčková, K. Urbánek

. 2023 ; 13 (7) : e071649. [pub] 20230730

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23016805

INTRODUCTION: Colistin is a lipopeptide antibiotic administered as an inactive prodrug-colistin methanesulfonate (CMS). Colistin is a drug with a narrow therapeutic window; the limiting factors are mainly nephrotoxicity and neurotoxicity, dependent on plasma concentrations. The number of patients with infections caused by multidrug-resistant Gram-negative bacteria sensitive only to colistin and the number of patients requiring extracorporeal membrane oxygenation (ECMO) support for severe respiratory failure increased significantly in association with COVID-19-induced infections. ECMO can generally affect the pharmacokinetics of drugs by creating a new compartment. METHODS AND ANALYSIS: The COL-ECMO2022 study is a prospective, non-randomised, single-centre, phase IV pharmacokinetic clinical trial designed to assess the influence of ECMO on the pharmacokinetics of colistin and CMS. Up to 30 patients treated with colistin will be included in the study and assigned to one of two arms, depending on the presence/absence of ECMO. All study participants will receive standard CMS dose intravenously. The plasma concentrations of colistin and CMS taken at defined intervals will be assessed by high-performance liquid chromatography-mass spectrometry. Patients will participate in the clinical trial for a maximum of three monitored dosing intervals. A population pharmacokinetic model will be developed to assess the influence of ECMO on pharmacokinetics. A difference greater than 25% is considered clinically significant. ETHICS AND DISSEMINATION: The study has been approved by the Ethics Committee of St. Anne's University Hospital Brno (Number 10ML/2022-AM). Related manuscripts will be submitted to peer-review journals. TRIAL REGISTRATION NUMBERS: EudraCT Number 2022-000291-19; NCT05542446.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016805
003      
CZ-PrNML
005      
20240206144118.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/bmjopen-2023-071649 $2 doi
035    __
$a (PubMed)37518089
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Suk, Pavel $u International Clinical Research Center, Saint Anne's University Hospital Brno, Brno, Czech Republic $u Department of Anaesthesiology and Intensive Care, Saint Anne's University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Changes of colistin pharmacokinetics in critically ill patients due to the extracorporeal membrane oxygenation: protocol for the COL-ECMO2022 trial - a prospective, non-randomised, open-label phase IV pharmacokinetic clinical trial / $c P. Suk, J. Rychlíčková, L. Součková, V. Kubíčková, K. Urbánek
520    9_
$a INTRODUCTION: Colistin is a lipopeptide antibiotic administered as an inactive prodrug-colistin methanesulfonate (CMS). Colistin is a drug with a narrow therapeutic window; the limiting factors are mainly nephrotoxicity and neurotoxicity, dependent on plasma concentrations. The number of patients with infections caused by multidrug-resistant Gram-negative bacteria sensitive only to colistin and the number of patients requiring extracorporeal membrane oxygenation (ECMO) support for severe respiratory failure increased significantly in association with COVID-19-induced infections. ECMO can generally affect the pharmacokinetics of drugs by creating a new compartment. METHODS AND ANALYSIS: The COL-ECMO2022 study is a prospective, non-randomised, single-centre, phase IV pharmacokinetic clinical trial designed to assess the influence of ECMO on the pharmacokinetics of colistin and CMS. Up to 30 patients treated with colistin will be included in the study and assigned to one of two arms, depending on the presence/absence of ECMO. All study participants will receive standard CMS dose intravenously. The plasma concentrations of colistin and CMS taken at defined intervals will be assessed by high-performance liquid chromatography-mass spectrometry. Patients will participate in the clinical trial for a maximum of three monitored dosing intervals. A population pharmacokinetic model will be developed to assess the influence of ECMO on pharmacokinetics. A difference greater than 25% is considered clinically significant. ETHICS AND DISSEMINATION: The study has been approved by the Ethics Committee of St. Anne's University Hospital Brno (Number 10ML/2022-AM). Related manuscripts will be submitted to peer-review journals. TRIAL REGISTRATION NUMBERS: EudraCT Number 2022-000291-19; NCT05542446.
650    _2
$a lidé $7 D006801
650    _2
$a kolistin $x terapeutické užití $7 D003091
650    12
$a mimotělní membránová oxygenace $7 D015199
650    _2
$a kritický stav $x terapie $7 D016638
650    _2
$a prospektivní studie $7 D011446
650    12
$a COVID-19 $7 D000086382
650    _2
$a antibakteriální látky $x farmakokinetika $7 D000900
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rychlíčková, Jitka $u International Clinical Research Center, Saint Anne's University Hospital Brno, Brno, Czech Republic rychlickova@med.muni.cz $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $1 https://orcid.org/0000000157645326
700    1_
$a Součková, Lenka $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Saint Anne's University Hospital, Brno, Czech Republic $7 xx0204153
700    1_
$a Kubíčková, Vendula $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Urbánek, Karel $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
773    0_
$w MED00184484 $t BMJ open $x 2044-6055 $g Roč. 13, č. 7 (2023), s. e071649
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37518089 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20240206144115 $b ABA008
999    __
$a ok $b bmc $g 2000383 $s 1203167
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c 7 $d e071649 $e 20230730 $i 2044-6055 $m BMJ open $n BMJ Open $x MED00184484
LZP    __
$a Pubmed-20231013

Najít záznam

Citační ukazatele

Možnosti archivace